TRANSFAC-Logo

TRANSFAC FACTOR TABLE, Release 2017.2 - public - 2017-06-30, (C) QIAGEN


AC T06131 XX ID T06131 XX DT 09.09.2004 (created); oke. DT 29.05.2015 (updated); asv. CO Copyright (C), QIAGEN. XX FA p63 XX SY Chronic ulcerative stomatitis protein; CUSP; Keratinocyte transcription factor KET; KET; p40; p51; p53-related p63 protein; p63; p73H; p73L; TP63; TP73L; Transformation-related protein 63; Tumor protein 63; tumor protein p63; tumor protein p73-like. XX OS human, Homo sapiens OC eukaryota; animalia; metazoa; chordata; vertebrata; tetrapoda; mammalia; eutheria; primates XX GE G009616 TP63; HGNC: TP63. XX CL C0057; P53; 6.3.1.0.2. XX SF generic entry for factors encoded by the human p63 (TP73L) gene; SF several alternative products are known, p63alpha T06132, p63beta T06133, p63gamma T06135, p63delta T06005, DeltaN p63alpha T06004, DeltaN p63beta T06134, DeltaNp63gamma T06136 [2] [3]; SF DeltaN variants lack N-terminal (potential) transactivation domain [2]; SF variants alpha, beta, gamma refer to different C termini [2]; SF DBD is highly conserved between p53, p73 and p63 [2]; SF forms stable homotetramers, is able to weakly associate with p73, but does not associate with p53 [1]; XX CP restricted number of tissues: skeletal muscle, placenta, mammary gland, prostate, trachea, thymus, salivary gland, uterus, heart, lung [6]; proliferating epithelial cells [2]; keratinocyte stem cells [5]; [2] [5] [6]. XX FF TAp63 variants are transcriptional activators [4] [6]; FF DeltaN variants can act as dominant-negative factors [2]; FF mutations are found in epithelial tumors [6]; FF identified as a marker of keratinocyte stem cells [5]; XX IN T22877 DeltaNp63alpha; Mammalia. IN T06138 p73; human, Homo sapiens. XX MX M00761 V$P53DECAMER_Q2. MX M01656 V$P63_01. MX M07138 V$TP63_02. XX BS R72121. BS R72123. BS R26473. BS R40236. BS R40269. BS R40376. BS R67989. BS R67994. BS R72798. BS R72800. XX DR TRANSPATH: MO000042291. DR UniProtKB: Q9H3D4; XX RN [1]; RE0024342. RX PUBMED: 10373484. RA Davison T. S., Vagner C., Kaghad M., Ayed A., Caput D., Arrowsmith C. H. RT p73 and p63 are homotetramers capable of weak heterotypic interactions with each other but not with p53. RL J. Biol. Chem. 274:18709-18714 (1999). RN [2]; RE0024711. RX PUBMED: 9774969. RA Yang A., Kaghad M., Wang Y., Gillett E., Fleming M. D., Dotsch V., Andrews N. C., Caput D., McKeon F. RT p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. RL Mol. Cell 2:305-316 (1998). RN [3]; RE0024715. RX PUBMED: 11477076. RA Klein C., Georges G., Kunkele K. P., Huber R., Engh R. A., Hansen S. RT High thermostability and lack of cooperative DNA binding distinguish the p63 core domain from the homologous tumor suppressor p53. RL J. Biol. Chem. 276:37390-37401 (2001). RN [4]; RE0024964. RX PUBMED: 10383130. RA Shimada A., Kato S., Enjo K., Osada M., Ikawa Y., Kohno K., Obinata M., Kanamaru R., Ikawa S., Ishioka C. RT The transcriptional activities of p53 and its homologue p51/p63: similarities and differences. RL Cancer Res. 59:2781-2786 (1999). RN [5]; RE0024968. RX PUBMED: 11248048. RA Pellegrini G., Dellambra E., Golisano O., Martinelli E., Fantozzi I., Bondanza S., Ponzin D., McKeon F., De Luca M. RT p63 identifies keratinocyte stem cells. RL Proc. Natl. Acad. Sci. USA 98:3156-3161 (2001). RN [6]; RE0024979. RX PUBMED: 9662378. RA Osada M., Ohba M., Kawahara C., Ishioka C., Kanamaru R., Katoh I., Ikawa Y., Nimura Y., Nakagawara A., Obinata M., Ikawa S. RT Cloning and functional analysis of human p51, which structurally and functionally resembles p53. RL Nat. Med. 4:839-843 (1998). RN [7]; RE0024980. RX PUBMED: 9662346. RA Trink B., Okami K., Wu L., Sriuranpong V., Jen J., Sidransky D. RT A new human p53 homologue. RL Nat. Med. 4:747-748 (1998). RN [8]; RE0040482. RX PUBMED: 12692135. RA Fomenkov A., Huang Y. P., Topaloglu O., Brechman A., Osada M., Fomenkova T., Yuriditsky E., Trink B., Sidransky D., Ratovitski E. RT P63 alpha mutations lead to aberrant splicing of keratinocyte growth factor receptor in the Hay-Wells syndrome RL J. Biol. Chem. 278:23906-14 (2003). RN [9]; RE0050295. RX PUBMED: 17581882. RA Sayan B. S., Sayan A. E., Yang A. L., Aqeilan R. I., Candi E., Cohen G. M., Knight R. A., Croce C. M., Melino G. RT Cleavage of the transactivation-inhibitory domain of p63 by caspases enhances apoptosis. RL Proc. Natl. Acad. Sci. USA 104:10871-10876 (2007). XX //